ES2338193B8 - Nuevas sales de amonafide. - Google Patents

Nuevas sales de amonafide. Download PDF

Info

Publication number
ES2338193B8
ES2338193B8 ES200800526A ES200800526A ES2338193B8 ES 2338193 B8 ES2338193 B8 ES 2338193B8 ES 200800526 A ES200800526 A ES 200800526A ES 200800526 A ES200800526 A ES 200800526A ES 2338193 B8 ES2338193 B8 ES 2338193B8
Authority
ES
Spain
Prior art keywords
amonafide
salts
new salts
histone deacetylase
enzyme inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200800526A
Other languages
English (en)
Other versions
ES2338193B2 (es
ES2338193A1 (es
Inventor
Miguel Fernandez Braña
Carlos Jose Boluda Cabrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRO ATLANTICO DEL MEDICAMENTO SA
Ct Atlantico Del Medicamento S A
Original Assignee
CENTRO ATLANTICO DEL MEDICAMENTO SA
Ct Atlantico Del Medicamento S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRO ATLANTICO DEL MEDICAMENTO SA, Ct Atlantico Del Medicamento S A filed Critical CENTRO ATLANTICO DEL MEDICAMENTO SA
Priority to ES200800526A priority Critical patent/ES2338193B8/es
Publication of ES2338193A1 publication Critical patent/ES2338193A1/es
Publication of ES2338193B2 publication Critical patent/ES2338193B2/es
Application granted granted Critical
Publication of ES2338193B8 publication Critical patent/ES2338193B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nuevas sales de Amonafide.
La invención comprende nuevas sales de Amonafide y su proceso de obtención. Las sales de la invención comprenden como catión el principio activo Amonafide, un conocido fármaco antitumoral. La novedad y actividad inventiva de la presente invención radica en que el anión de la sal de Amonafide se selecciona entre los ácidos carboxílicos inhibidores del enzima histona desacetilasa, enzima implicado en la proliferación de las células cancerígenas. Otro aspecto de la invención consiste en el uso de las sales de Amonafide con ácidos inhibidores del enzima histona desacetilasa, en la fabricación de medicamentos, composiciones y formulaciones farmacéuticas, útiles en el tratamiento del cáncer.
ES200800526A 2008-02-25 2008-02-25 Nuevas sales de amonafide. Expired - Fee Related ES2338193B8 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200800526A ES2338193B8 (es) 2008-02-25 2008-02-25 Nuevas sales de amonafide.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200800526A ES2338193B8 (es) 2008-02-25 2008-02-25 Nuevas sales de amonafide.

Publications (3)

Publication Number Publication Date
ES2338193A1 ES2338193A1 (es) 2010-05-04
ES2338193B2 ES2338193B2 (es) 2011-01-25
ES2338193B8 true ES2338193B8 (es) 2011-07-19

Family

ID=42109698

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200800526A Expired - Fee Related ES2338193B8 (es) 2008-02-25 2008-02-25 Nuevas sales de amonafide.

Country Status (1)

Country Link
ES (1) ES2338193B8 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922771A1 (de) * 1989-07-11 1991-01-24 Knoll Ag Amonafide-salze
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts

Also Published As

Publication number Publication date
ES2338193B2 (es) 2011-01-25
ES2338193A1 (es) 2010-05-04

Similar Documents

Publication Publication Date Title
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CO2018004589A2 (es) Sales de valbenazina y polimorfos de las mismas
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
AR119552A2 (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UY30338A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos.
CO6531464A2 (es) Morfolinotiazoles como moduladores alostéricos positivos alfa 7
UY35024A (es) Inhibidores de glucosilceramida sintasa
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
TR201904614T4 (tr) Novel pyrazole derivative.
CU20140043A7 (es) Benzilindazoles sustituidos como inhibidores de la quinasa bub1
UY32502A (es) Agentes antihelmínticos y su utilización
GT200500132A (es) Formulaciones acuosas concentradas para la proteccion de las plantas
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
NI201300018A (es) Promotores de apoptosis de n - acilsulfonamidas
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
BR112014023347A2 (pt) conjugados de ácido borônico de análogos oligonucleotídeos

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20100504

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2338193

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20110113

FD2A Announcement of lapse in spain

Effective date: 20230626